macular degeneration, X-linked atrophic

disease
On this page

Also known as macular degeneration, X-linked atrophic, X-linked recessive

Summary

macular degeneration, X-linked atrophic (MONDO:0010443) is a disease with 1 cohort gene.

At a glance

  • Cohort genes: 1
  • ClinVar variants: 30

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namemacular degeneration, X-linked atrophic
Mondo IDMONDO:0010443
OMIM300834
DOIDDOID:0112157
UMLSC3151784
MedGen463134
GARD0015268
Is cancer (heuristic)no

Also known as: macular degeneration, X-linked atrophic · macular degeneration, X-linked atrophic, X-linked recessive

Data availability: 30 ClinVar variants · 1 GenCC gene-disease record.

Disease family

Classification path: disease › human disease › disease by body system or component › nervous system disorderretinal disorderretinal degenerationinherited retinal dystrophycone-rod dystrophymacular degeneration, X-linked atrophic

Related subtypes (27): cone-rod dystrophy 2, cone-rod dystrophy 1, cone-rod dystrophy 5, cone-rod dystrophy 6, cone dystrophy 3, cone-rod dystrophy 7, cone-rod dystrophy 3, Leber congenital amaurosis 4, cone-rod dystrophy 8, Newfoundland cone-rod dystrophy, cone-rod dystrophy 13, cone-rod dystrophy 10, cone-rod dystrophy 11, retinal cone dystrophy 4, cone-rod dystrophy 12, cone-rod dystrophy 9, cone-rod dystrophy 15, cone-rod dystrophy 16, cone-rod dystrophy 17, cone-rod dystrophy 18, cone-rod dystrophy 19, cone-rod dystrophy 20, cone-rod dystrophy 21, X-linked cone-rod dystrophy, cone-rod dystrophy 22, cone-rod dystrophy 14, cone-rod dystrophy 24

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

ClinVar germline variants

30 retrieved; paginated sample, class counts are floors:

7 benign, 6 pathogenic, 6 likely pathogenic, 4 conflicting classifications of pathogenicity, 4 uncertain significance, 2 pathogenic/likely pathogenic, 1 likely benign

ClinVarVariant (HGVS)GeneClassificationReview
1707409NM_001034853.2(RPGR):c.1302dup (p.Leu435fs)RPGRPathogenicreviewed by expert panel
216990NM_001034853.2(RPGR):c.3178_3179del (p.Glu1060fs)RPGRPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
3382894NM_001034853.2(RPGR):c.2872del (p.Glu958fs)RPGRPathogenic/Likely pathogeniccriteria provided, multiple submitters, no conflicts
3598278NM_001034853.2(RPGR):c.1506+1G>TRPGRPathogenicreviewed by expert panel
438142NM_001034853.2(RPGR):c.2236_2237del (p.Glu746fs)RPGRPathogenicreviewed by expert panel
866129NM_001034853.2(RPGR):c.2917G>T (p.Glu973Ter)RPGRPathogeniccriteria provided, multiple submitters, no conflicts
866844NM_001034853.2(RPGR):c.2260G>T (p.Glu754Ter)RPGRPathogenicreviewed by expert panel
91389NM_001034853.2(RPGR):c.2405_2406del (p.Glu802fs)RPGRPathogenicreviewed by expert panel
1802237NM_001034853.2(RPGR):c.1753+2T>GRPGRLikely pathogeniccriteria provided, single submitter
2110430NM_001034853.2(RPGR):c.620-2A>GRPGRLikely pathogeniccriteria provided, multiple submitters, no conflicts
2664727NM_001034853.2(RPGR):c.3238C>T (p.Gln1080Ter)RPGRLikely pathogeniccriteria provided, single submitter
3598276NM_001034853.2(RPGR):c.3255C>G (p.Tyr1085Ter)RPGRLikely pathogeniccriteria provided, single submitter
3598277NM_001034853.2(RPGR):c.3151G>T (p.Glu1051Ter)RPGRLikely pathogeniccriteria provided, single submitter
867083NM_001034853.2(RPGR):c.3300_3301del (p.His1100fs)RPGRLikely pathogeniccriteria provided, multiple submitters, no conflicts
1412206NM_001034853.2(RPGR):c.2691GGA[1] (p.Glu899del)RPGRConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1462786NM_001034853.2(RPGR):c.2203_2226del (p.His735_Glu742del)RPGRConflicting classifications of pathogenicitycriteria provided, conflicting classifications
1802282NM_001034853.2(RPGR):c.3263_3266del (p.Val1088fs)RPGRConflicting classifications of pathogenicitycriteria provided, conflicting classifications
414013NM_001034853.2(RPGR):c.1708A>G (p.Thr570Ala)RPGRConflicting classifications of pathogenicitycriteria provided, conflicting classifications
2061340NM_001034853.2(RPGR):c.2489AGG[2] (p.Glu832del)RPGRUncertain significancecriteria provided, multiple submitters, no conflicts
2585326NM_001034853.2(RPGR):c.1496T>C (p.Ile499Thr)RPGRUncertain significancecriteria provided, single submitter
2903518NM_001034853.2(RPGR):c.1484A>G (p.Glu495Gly)RPGRUncertain significancecriteria provided, multiple submitters, no conflicts
3892326NM_001034853.2(RPGR):c.3062T>G (p.Val1021Gly)RPGRUncertain significancecriteria provided, single submitter
100560NM_001034853.2(RPGR):c.223A>G (p.Ile75Val)RPGRBenignreviewed by expert panel
1212352NM_001034853.2(RPGR):c.2793G>A (p.Glu931=)RPGRLikely benigncriteria provided, multiple submitters, no conflicts
1276872NM_001034853.2(RPGR):c.2057T>A (p.Met686Lys)RPGRBenignreviewed by expert panel
227048NM_000328.3(RPGR):c.2241+11T>CRPGRBenigncriteria provided, multiple submitters, no conflicts
255834NM_000328.3(RPGR):c.2149+46C>TRPGRBenigncriteria provided, multiple submitters, no conflicts
255836NM_001034853.2(RPGR):c.552G>T (p.Gln184His)RPGRBenignreviewed by expert panel
454510NM_001034853.2(RPGR):c.1240G>C (p.Glu414Gln)RPGRBenignreviewed by expert panel
92849NM_001034853.2(RPGR):c.1164G>A (p.Ala388=)RPGRBenigncriteria provided, multiple submitters, no conflicts

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 10 · Orphanet: 5 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

GenCC gene–disease validity (cohort genes)

the Disease column is the GenCC-asserted condition — a cohort gene’s strongest validity may be for a related predisposition syndrome.

GeneClassificationInheritanceDiseaseRecords
RPGRLimitedX-linkedmacular degeneration, X-linked atrophic10

Orphanet rare-disease linkage (cohort genes)

GeneOrphanet IDRare disease
RPGROrphanet:1872Cone rod dystrophy
RPGROrphanet:244Primary ciliary dyskinesia
RPGROrphanet:247522Primary ciliary dyskinesia-retinitis pigmentosa syndrome
RPGROrphanet:49382Achromatopsia
RPGROrphanet:791Retinitis pigmentosa

Cohort genes → proteins

1 cohort genes, 1 distinct canonical proteins.

Evidence partition

SubsetGenes
multi_evidence1

Cohort genes (full)

SymbolHGNCEnsemblUniProtNameEvidence
RPGRHGNC:10295ENSG00000156313Q92834X-linked retinitis pigmentosa GTPase regulatorgencc,clinvar

Cohort function summary

Lead sentence per gene, UniProt-curated.

SymbolProtein nameFunction (lead sentence)
RPGRX-linked retinitis pigmentosa GTPase regulatorActs as a guanine-nucleotide releasing factor (GEF) for RAB8A and RAB37 by promoting the conversion of inactive RAB-GDP to the active form RAB-GTP.

Protein-family classification

Druggable: 0 · Difficult: 0 · Unknown: 1 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

FamilyGenesFoldFDR
Other/Unknown11.8×0.558

Per-gene assignment

SymbolFamilyDruggable?ECInterPro (top 3)
RPGROther/UnknownnoReg_chr_condens, RCC1/BLIP-II, Signaling_Regulatory_Domain

Expression context

Cohort genes with no expression data: 0.

1 cohort gene are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

BucketGenes
narrow (1-5 tissues)0
moderate (6-20)0
broad (>20)1
unknown0

Top tissues across cohort

TissueCohort genes
bronchial epithelial cell1
right uterine tube1
sperm1

Per-gene tissue summary (top 30)

SymbolBgee breadthFANTOM5 breadthSCXATop tissues
RPGR281ubiquitousmarkersperm, bronchial epithelial cell, right uterine tube

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

SymbolInteractor count
RPGR2,231

Structural data

PDB: 1 · AlphaFold-only: 0 · No structure: 0

Cohort genes with PDB structures (top 30)

SymbolUniProtPDB entries
RPGRQ928343

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 0. Enrichment computed across 1 evidence-associated genes (0 with Reactome annotation).

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 1 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO termCohort genesFoldFDRSample cohort genes
protein localization to non-motile cilium14213.0×0.002RPGR
eye photoreceptor cell development1842.6×0.005RPGR
intraciliary transport1561.7×0.005RPGR
positive regulation of autophagy1208.1×0.011RPGR
visual perception179.5×0.017RPGR
ubiquitin-dependent protein catabolic process174.2×0.017RPGR
cilium assembly173.6×0.017RPGR
intracellular protein transport164.8×0.017RPGR
protein ubiquitination141.4×0.024RPGR

Therapeutics

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 1

Druggability breadth: 0 of 1 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

SymbolMoleculesMax phase
RPGR00

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 0.

Pharmacogenomics

Cohort genes with a PharmGKB record: 1; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

TierDefinitionGenesSymbols
AApproved (phase 4 drug)0
BPhased (≥1) drug, not yet approved0
CDruggable family + PDB, no drug0
DDruggable family + AlphaFold only, no drug0
EDifficult family or no structure, no drug1RPGR

Undrugged target profiles

1 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

SymbolChEMBL assaysDrugged partners (top 3)
RPGR0

Clinical trials & evidence

Clinical trials

Clinical trials: 0.